SERTA domain-containing protein 2 (SERTAD2)

SERTA domain-containing protein 2 (SERTAD2) is a transcriptional co-regulator that acts at E2F-responsive promoters, integrating signals from PHD- and bromodomain-containing transcription factors. It can function either as a coactivator or corepressor of critical transcription complexes, modulating gene expression associated with cell cycle progression and fat metabolism. SERTAD2 plays a pivotal role in energy homeostasis, with knockout studies in mice showing resistance to obesity and insulin resistance, suggesting enhanced lipid turnover and energy expenditure. Its expression is tightly regulated through the cell cycle, peaking at the G1/S boundary, and is subject to CRM1-mediated nuclear export and proteasomal degradation. SERTAD2 is frequently overexpressed in multiple human tumors, including lung cancer (where it is upregulated downstream of REV1/Rad18 in the DNA damage response), emphasizing its relevance in oncogenesis as well as metabolic disorders. Currently, there are no approved drugs directly targeting SERTAD2, but its biological significance in cancer and metabolism positions it as a candidate therapeutic target for future research[1][2][3][4].

Other names

TRIP-Br2TRIPBR2Sei-2KIAA0127SERTA domain containing 2SERTA domain-containing protein 2Transcriptional regulator interacting with the PHD-bromodomain 2SEI-2SRTD2_HUMAN

Not directly applicable; may become relevant if drugs are developed that inhibit its co-regulatory function for E2F-responsive transcription or modulate its effect on fat metabolism and cell proliferation